Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity

A. Serretti, R. Zanardi, D. Rossini, C. Cusin, R. Lilli, E. Smeraldi

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence of 5-HTTLPR polymorphism. If confirmed, these results may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.

Original languageEnglish
Pages (from-to)586-592
Number of pages7
JournalMolecular Psychiatry
Volume6
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Fluvoxamine
Tryptophan Hydroxylase
Pindolol
Serotonin Plasma Membrane Transport Proteins
Antidepressive Agents
Depression
Genes
Inpatients
Therapeutics
Placebos
Pharmacology
Polymerase Chain Reaction

Keywords

  • Antidepressant treatment
  • Fluvoxamine
  • Mood disorders
  • Pindolol
  • Serotonin transporter
  • Tryptophan hydroxylase

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health

Cite this

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. / Serretti, A.; Zanardi, R.; Rossini, D.; Cusin, C.; Lilli, R.; Smeraldi, E.

In: Molecular Psychiatry, Vol. 6, No. 5, 2001, p. 586-592.

Research output: Contribution to journalArticle

Serretti, A, Zanardi, R, Rossini, D, Cusin, C, Lilli, R & Smeraldi, E 2001, 'Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity', Molecular Psychiatry, vol. 6, no. 5, pp. 586-592. https://doi.org/10.1038/sj.mp.4000876
Serretti, A. ; Zanardi, R. ; Rossini, D. ; Cusin, C. ; Lilli, R. ; Smeraldi, E. / Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. In: Molecular Psychiatry. 2001 ; Vol. 6, No. 5. pp. 586-592.
@article{34ffa43628e84cdeb014a5ae0671054c,
title = "Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity",
abstract = "The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence of 5-HTTLPR polymorphism. If confirmed, these results may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.",
keywords = "Antidepressant treatment, Fluvoxamine, Mood disorders, Pindolol, Serotonin transporter, Tryptophan hydroxylase",
author = "A. Serretti and R. Zanardi and D. Rossini and C. Cusin and R. Lilli and E. Smeraldi",
year = "2001",
doi = "10.1038/sj.mp.4000876",
language = "English",
volume = "6",
pages = "586--592",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity

AU - Serretti, A.

AU - Zanardi, R.

AU - Rossini, D.

AU - Cusin, C.

AU - Lilli, R.

AU - Smeraldi, E.

PY - 2001

Y1 - 2001

N2 - The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence of 5-HTTLPR polymorphism. If confirmed, these results may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.

AB - The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence of 5-HTTLPR polymorphism. If confirmed, these results may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.

KW - Antidepressant treatment

KW - Fluvoxamine

KW - Mood disorders

KW - Pindolol

KW - Serotonin transporter

KW - Tryptophan hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=0034885170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034885170&partnerID=8YFLogxK

U2 - 10.1038/sj.mp.4000876

DO - 10.1038/sj.mp.4000876

M3 - Article

VL - 6

SP - 586

EP - 592

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 5

ER -